Decision on future reimbursement status of medicines in ATC group C05 (vasoprotectives)

On 27 June 2011, the Danish Medicines Agency decided on the future reimbursement status of medicines in ATC group C05 (vasoprotectives). These medicines will still not be eligible for general reimbursement.

In the box to the right, you can find a link to the letter containing the decision which the Danish Medicines Agency has sent to companies which hold a marketing authorisation for medicines comprised by the decision (in Danish only).